Recap: Veru Q4 Earnings

 

Shares of Veru VERU moved higher by 4.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 160.00% year over year to $0.03, which beat the estimate of ($0.04).

Revenue of $11,749,000 up by 34.61% year over year, which beat the estimate of $10,630,000.

Guidance

Veru hasn't issued any earnings guidance for the time being.

Veru hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Dec 09, 2020

Time: 08:00 AM

ET Webcast URL: https://verupharma.com/investors/presentations-conference-calls/

Price Action

52-week high: $4.74

Company's 52-week low was at $2.10

Price action over last quarter: Up 26.12%

Company Overview

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...